KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBITDA Margin (2017 - 2025)

Sarepta Therapeutics has reported EBITDA Margin over the past 12 years, most recently at 92.92% for Q4 2025.

  • Quarterly results put EBITDA Margin at 92.92% for Q4 2025, down 11748.0% from a year ago — trailing twelve months through Dec 2025 was 31.61% (down 4419.0% YoY), and the annual figure for FY2025 was 31.83%, down 4330.0%.
  • EBITDA Margin for Q4 2025 was 92.92% at Sarepta Therapeutics, down from 44.99% in the prior quarter.
  • Over the last five years, EBITDA Margin for SRPT hit a ceiling of 32.21% in Q2 2025 and a floor of 2342.69% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 42.66% (2025), compared with a mean of 253.89%.
  • Biggest five-year swings in EBITDA Margin: tumbled -229274bps in 2023 and later skyrocketed 235104bps in 2024.
  • Sarepta Therapeutics' EBITDA Margin stood at 60.55% in 2021, then skyrocketed by 77bps to 13.86% in 2022, then skyrocketed by 132bps to 4.38% in 2023, then soared by 461bps to 24.56% in 2024, then crashed by -478bps to 92.92% in 2025.
  • The last three reported values for EBITDA Margin were 92.92% (Q4 2025), 44.99% (Q3 2025), and 32.21% (Q2 2025) per Business Quant data.